C-reactive protein and risk of colorectal adenomas or serrated polyps: A prospective study

Cancer Prevention Research

Volumn 7, Issue 11, 2014, Pages 1122-1127

  Crockett, Seth D ^a   Mott, Leila A ^b   Barry, Elizabeth L ^b   Figueiredo, Jane C ^c   Burke, Carol A ^d   Baxter, Gwen J ^e   Sandler, Robert S ^a   Baron, John A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; PLACEBO; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL POLYP; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERRATED POLYP; ADENOMA; BLOOD; CLINICAL TRIAL; COLON POLYP; COLORECTAL TUMOR; INFLAMMATION; METABOLISM; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; POISSON DISTRIBUTION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84910151311     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0167     Document Type: Article

References (25)

1. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
2. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977;1:195-7.
3. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
4. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res 2010;8:89-95.
5. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216-22.
6. Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, Kemona-Chetnik I, Kemona H. Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 2007;120:585-90.
7. Zaloudik J, Lauerova L, Janakova L, Talac R, Simickova M, Nekulova M, et al. Signi ficance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999;46:220-7.
8. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008;123:1133-40.
9. Otake T, Uezono K, Takahashi R, Fukumoto J, Tabata S, Abe H, et al. C-reactive protein and colorectal adenomas: self Defense forces health study. Cancer Sci 2009;100:709-14.
10. Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang JT, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-25.
11. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res 2011;4:1172-80.
12. Tsilidis KK, Erlinger TP, Rifai N, Hoffman S, Hoffman-Bolton J, Helzlsouer KJ, et al. C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2008;19:559-67.
13. Ognjanovic S, Yamamoto J, Saltzman B, Franke A, Ognjanovic M, Yokochi L, et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control 2010;21:1131-8.
14. Gunter MJ, Cross AJ, Huang WY, Stanczyk FZ, Purdue M, Xue X, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers Prev 2011;20:537-44.
15. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7.
16. Snover D, Ahnen D, Burt R, Odze R. Serrated polyps of the colon and rectum and serrated ("hyperplastic") polyposis. In: Bozman F, Carneiro F, Hruban R, Theise N, editors. WHO classification of tumours of the digestive system. Berlin: Springer-Verlag; 2010.
17. Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res 2011;4:1645-54.
18. Grey A, Gamble G, Ames R, Horne A, Mason B, Reid IR. Calcium supplementation does not affect CRP levels in postmenopausal women-a randomized controlled trial. Osteoporos Int 2006;17:1141-5.
19. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
20. Kushner I, Samols D, Magrey M. A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation. Arthritis Care Res 2010;62:442-6.
21. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, et al. Genetic variation is associated with C-reactive protein levels in the third national health and nutrition examination survey. Circulation 2006;114:2458-65.
22. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, et al. Association of polymorphismsin theCRPgene with circulating Creactive protein levels and cardiovascular events. JAMA 2006;296:2703-11.
23. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Creactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps. Pharmacogenet Genomics 2009;19:113-20.
24. Slattery ML, Curtin K, Poole EM, Duggan DJ, Samowitz WS, Peters U, et al. Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer 2011;128:2726-34.
25. Higuchi T, Jass JR. My approach to serrated polyps of the colorectum. J Clin Pathol 2004;57:682-6.